BIO BIO-RAD LABORATORIES, INC.
Laboratory Analytical Instruments · NYSE · SEC CIK 12208 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.4%
TTM net income YoY251.3%
TTM EPS YoY254.8%
Revenue 3-yr CAGR-1.6%
Net income 3-yr CAGR—
Margins
Gross margin51.3%
Operating margin-2.4%
Net margin39.5%
FCF margin12.7%
EBITDA margin—
Returns
ROE14.3%
ROA10.0%
ROIC (approx.)-0.6%
Asset turnover0.25x
Leverage & solvency
Liabilities / assets29.5%
Debt / equity0.11x
Current ratio3.18x
Interest coverage-1.27x
Cash quality & payout
Operating cash flow / net income0.46x
Accruals ratio5.4%
Payout ratio—
Capex / revenue5.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.58B | $2.57B |
| Cost of revenue | $1.24B | $1.19B |
| Gross profit | $1.34B | $1.38B |
| R&D expense | $275.60M | $295.90M |
| SG&A expense | $844.30M | $814.00M |
| Operating income | $47.20M | $269.00M |
| Interest expense | $49.00M | $48.90M |
| Pretax income | $995.50M | -$2.34B |
| Income tax | $235.60M | -$498.30M |
| Net income | $759.90M | -$1.84B |
| EBITDA | $212.60M | $420.60M |
| EPS (basic) | 27.87 | -65.36 |
| EPS (diluted) | 27.85 | -65.36 |
| Weighted avg. shares (diluted) | 27.28M | 28.21M |
| Banking | ||
| Provision for credit losses | $1.40M | $0 |
| Balance sheet | ||
| Cash & equivalents | $529.80M | $489.80M |
| Short-term investments | $1.01B | $1.18B |
| Receivables | $460.60M | $452.50M |
| Inventory | $740.70M | $760.00M |
| Current assets | $2.91B | $3.03B |
| PP&E, net | $539.90M | $528.10M |
| Goodwill | $579.80M | $410.50M |
| Intangibles | $174.30M | $293.60M |
| Total assets | $10.58B | $9.36B |
| Current liabilities | $517.00M | $467.80M |
| Long-term debt | $1.20B | $1.20B |
| Total debt | $1.20B | $1.20B |
| Total liabilities | $3.12B | $2.79B |
| Shareholders' equity | $7.45B | $6.57B |
| Net debt | $671.90M | $710.60M |
| Cash flow statement | ||
| Operating cash flow | $532.20M | $455.20M |
| Capital expenditure | $157.60M | $165.60M |
| Free cash flow | $374.60M | $289.60M |
| Investing cash flow | -$189.70M | -$160.20M |
| Financing cash flow | -$283.20M | -$218.80M |
| Depreciation & amortization | $165.40M | $151.60M |
| Stock-based compensation | $58.00M | $62.30M |
| Share buybacks | $295.50M | $203.60M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.